Zentalis Pharmaceuticals (NASDAQ:ZNTL) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a sell rating to a strong sell rating in a research report report published on Saturday morning.

Several other research analysts have also commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Guggenheim upped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective for the company. Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.75.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $4.22 on Friday. The business has a 50 day simple moving average of $4.31 and a 200-day simple moving average of $3.59. The firm has a market capitalization of $300.42 million, a PE ratio of -2.16 and a beta of 1.92. Zentalis Pharmaceuticals has a 1 year low of $1.21 and a 1 year high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, equities research analysts expect that Zentalis Pharmaceuticals will post -1.83 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several large investors have recently modified their holdings of the business. JPMorgan Chase & Co. increased its position in shares of Zentalis Pharmaceuticals by 31.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 723,075 shares of the company’s stock worth $1,092,000 after purchasing an additional 172,628 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in Zentalis Pharmaceuticals during the first quarter worth about $257,000. Anfield Capital Management LLC boosted its stake in Zentalis Pharmaceuticals by 239.9% during the fourth quarter. Anfield Capital Management LLC now owns 242,605 shares of the company’s stock worth $328,000 after buying an additional 171,228 shares during the period. 5AM Venture Management LLC increased its position in shares of Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after acquiring an additional 3,457,913 shares during the last quarter. Finally, Ishara Investments LP acquired a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $1,782,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.